gvtcx

Aseptically Prepared Systemic Anti-Cancer Therapy Medicines

Mid South Essex NHS Foundation Trust Published 13 Apr 2026 Find a Tender
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£850,000,000
Statusactive
Category (CPV) 33600000
RegionEast Midlands, West Midlands, South East
Deadline11 May 2026
Procedureopen
SME suitableYes
OCIDocds-h6vhtk-051cde

description

This framework agreement is for the supply of a range of aseptically prepared, batch manufactured systemic anti-cancer therapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific systemic anti-cancer therapy drugs, CIVAs, and provisions for stock inventory management and supply of compounded systemic anti-cancer therapy.

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

3 notices published against this procurement.

PublishedTypeRegimeNotice
22 May 2025 Pipeline notice (UK1) Procurement Act 2023 024556-2025
12 Aug 2025 Preliminary market engagement (UK2) Procurement Act 2023 048018-2025
13 Apr 2026 Tender notice (UK4) Procurement Act 2023 033144-2026

more from Mid South Essex NHS Foundation Trust

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.